Valuation: Neurizon Therapeutics Limited

Capitalization 7.63Cr 4.98Cr 4.3Cr 4.05Cr 3.66Cr 6.78Cr 426.11Cr 47Cr 18Cr 195.77Cr 19Cr 18Cr 715.14Cr P/E ratio 2023
-3.88x
P/E ratio 2024 -9.42x
Enterprise value 6.56Cr 4.28Cr 3.69Cr 3.48Cr 3.15Cr 5.82Cr 366.19Cr 40Cr 16Cr 168.24Cr 16Cr 16Cr 614.58Cr EV / Sales 2023
6.39x
EV / Sales 2024 90.4x
Free-Float
79.71%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.23%
1 week+14.29%
Current month+18.52%
1 month+10.34%
3 months+52.38%
6 months-11.11%
Current year-5.88%
More quotes
1 week 0.14
Extreme 0.145
0.16
1 month 0.14
Extreme 0.135
0.16
Current year 0.1
Extreme 0.096
0.18
1 year 0.1
Extreme 0.096
0.24
3 years 0.06
Extreme 0.06
0.54
5 years 0.06
Extreme 0.06
0.54
10 years 0.03
Extreme 0.03
0.54
More quotes
Manager TitleAgeSince
Chief Executive Officer - 01/09/2023
Director of Finance/CFO - 22/04/2025
Corporate Secretary - 24/05/2024
Director TitleAgeSince
Director/Board Member - 09/05/2024
Chairman - 17/05/2024
Director/Board Member - 31/05/2024
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.23%+14.29%-31.91%+97.53% 4.98Cr
+0.42%+6.05%-6.37%+173.40% 73TCr
+0.90%+1.95%+7.74%-9.21% 38TCr
+0.48%+8.92%-47.53%+32.18% 36TCr
+0.48%+2.64%+15.85%+34.37% 34TCr
+1.00%+1.83%+11.95%-13.17% 27TCr
+1.10%+1.45%+3.60%+16.86% 24TCr
+1.14%+3.08%-11.52%+11.97% 23TCr
+1.87%+5.41%-37.16%-6.15% 21TCr
+1.88%+3.55%-1.26%+23.87% 16TCr
Average +1.14%+4.50%-9.66%+36.17% 29.06TCr
Weighted average by Cap. +0.68%+4.21%-6.81%+52.27%
See all sector performances

Financials

2023 2024
Net sales 38.19L 24.9L 21.52L 20.26L 18.33L 33.91L 21Cr 2.35Cr 91.89L 9.8Cr 93.43L 91.46L 36Cr 8L 5L 5L 4L 4L 7L 4.7Cr 51.87L 20.25L 2.16Cr 20.59L 20.16L 7.89Cr
Net income -62.12L -40.5L -34.99L -32.95L -29.81L -55.15L -35Cr -3.83Cr -1.49Cr -16Cr -1.52Cr -1.49Cr -58Cr -76.73L -50.03L -43.23L -40.7L -36.83L -68.13L -43Cr -4.73Cr -1.85Cr -20Cr -1.88Cr -1.84Cr -72Cr
Net Debt -16.73L -10.91L -9L -9L -8L -14.85L -9.34Cr -1.03Cr -40.25L -4.29Cr -40.92L -40.06L -16Cr -1.07Cr -69.97L -60.45L -56.91L -51.5L -95.27L -60Cr -6.61Cr -2.58Cr -28Cr -2.62Cr -2.57Cr -100.56Cr
More financial data * Estimated data
Logo Neurizon Therapeutics Limited
Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
Employees
4
More about the company
Date Price Change Volume
13/25/13 0.1600 $ +3.23% 5,03,081
12/25/12 0.1550 $ +3.33% 12,29,085
11/25/11 0.1500 $ -3.23% 5,54,603
10/25/10 0.1550 $ +10.71% 7,34,651
06/25/06 0.1400 $ 0.00% 26,844

Delayed Quote Australian S.E., June 13, 2025 at 11:40 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1550AUD
Average target price
0.4200AUD
Spread / Average Target
+170.97%
Consensus

Annual profits - Rate of surprise